Technology
Health
Pharmaceutical

Novan

$2.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-4.33%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Novan and other stocks, options, ETFs, and crypto commission-free!

About

Novan, Inc. Common Stock, also called Novan, is a biotechnology company, which engages in leveraging nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Read More Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.

Employees
48
Headquarters
Morrisville, North Carolina
Founded
2006
Market Cap
60.19M
Price-Earnings Ratio
Dividend Yield
Average Volume
152.55K
High Today
$2.29
Low Today
$2.07
Open Price
$2.15
Volume
265.86K
52 Week High
$3.25
52 Week Low
$0.65

Collections

Technology
Health
Pharmaceutical
Biotechnology
Medical
2016 IPO
US
North America

News

Yahoo FinanceMay 7

Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the treatment of atopic dermatitis and Phase 2 trial with SB206 gel for the treatment of molluscum contagiosum will be presented at the 77th Annual Meeting of the Annual Meeting of the Society for Investigative Dermatology. The meeting will be held May 8-11, 2019 in Chicago, Illinois. Clinical and biomarker results from t...

322
Yahoo FinanceMay 6

Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.

SAN DIEGO--(BUSINESS WIRE)-- Phase 3 drug candidate targeting molluscum Ligand Pharmaceuticals Incorporated (LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum. Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 million in regulatory and commercial milestones. Novan is responsible for all exp...

238
Yahoo FinanceMay 1

Novan Confirms Corporate Update Conference Call and Webcast

MORRISVILLE, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019 at 8:15 am Eastern Time to provide an update on the Company’s recent financing, clinical development plan and business model. A moderated question and answer session will be available after the update. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to particip...

403

Earnings

-$0.51
-$0.25
$0.02
$0.28
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.27 per share
Actual
Expected May 28, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.